STOCK TITAN

[SCHEDULE 13G/A] FENNEC PHARMACEUTICALS INC. Amended Passive Investment Disclosure

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

FENNEC PHARMACEUTICALS INC. Schedule 13G/A (Amendment No. 3) reports that Solas Capital Management, LLC and Frederick Tucker Golden each hold 2,482,198 common shares, representing 7.2% of the class based on 34,475,178 shares outstanding as of March 20, 2026.

The filing states the reported holdings reflect shared voting and dispositive power of 2,482,198 shares and confirms the investment adviser/portfolio manager relationship; the Funds disclaim beneficial ownership pursuant to Rule 13d-4.

Positive

  • None.

Negative

  • None.

Insights

Ownership disclosure shows a 7.2% stake held with shared voting and dispositive power.

The filing documents that Solas Capital Management, LLC and portfolio manager Frederick Tucker Golden each report 2,482,198 shares, equal to 7.2% of 34,475,178 outstanding as of March 20, 2026. The holdings are reported as shared voting and dispositive power.

The disclosure also cites Rule 13d-4 disclaimers by the Fund and the Other Fund; subsequent filings would show any changes to position size or voting arrangements.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





31447P100

(CUSIP Number)
03/31/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Solas Capital Management, LLC
Signature:/s/ Frederick Tucker Golden
Name/Title:General Partner, Solas Capital Holdings, LP, its Member
Date:05/15/2026
FREDERICK TUCKER GOLDEN
Signature:/s/ Frederick Tucker Golden
Name/Title:Frederick Tucker Golden
Date:05/15/2026